Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Alzheimers Dis. 2010;21(3):833-42. doi: 10.3233/JAD-2010-091711.

Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels.

Author information

  • 1Department of Biology, Brigham Young University, Provo, UT, USA.

Abstract

Recent large-scale genetic studies of late-onset Alzheimer's disease have identified risk variants in CALHM1, GAB2, and SORL1. The mechanisms by which these genes might modulate risk are not definitively known. CALHM1 and SORL1 may alter amyloid-β (Aβ) levels and GAB2 may influence phosphorylation of the tau protein. In this study we have analyzed disease associated genetic variants in each of these genes for association with cerebrospinal fluid (CSF) Aβ or tau levels in 602 samples from two independent CSF series. We failed to detect association between CSF Aβ42 levels and single nucleotide polymorphisms in SORL1 despite substantial statistical power to detect association. While we also failed to detect association between variants in GAB2 and CSF tau levels, power to detect this association was limited. Finally, our data suggest that the minor allele of rs2986017, in CALHM1, is marginally associated with CSF Aβ42 levels. This association is consistent with previous reports that this non-synonymous coding substitution results in increased Aβ levels in vitro and provides support for an Aβ-related mechanism for modulating risk for Alzheimer's disease.

PMID:
20634593
[PubMed - indexed for MEDLINE]
PMCID:
PMC3032214
Free PMC Article

Images from this publication.See all images (1)Free text

Figure 1

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for IOS Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk